Bernstein Maintains Market Perform on Revolution Medicines, Raises Price Target to $179

Benzinga Newsdesk www.benzinga.com Positive 86.0%

Neg 0% Neu 0% Pos 86%

Bernstein analyst Jeffrey Walch maintains Revolution Medicines (NASDAQ:RVMD) with a Market Perform and raises the price target from $151 to $179.